Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series

Rhea-AI Summary

Pear Therapeutics, Inc. (NASDAQ: PEAR) will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on January 24 at 11:00 a.m. ET. Dr. Corey McCann, President and CEO, will discuss Pear's advancements in market access for its prescription digital therapeutics (PDTs).

Pear is a leader in developing software-based medicines, aiming to enhance patient care through clinically validated therapeutics. Their first PDT, reSET®, was the first to receive FDA marketing authorization for treating substance use disorder. The company has a strong pipeline, including reSET-O® and Somryst®, further solidifying its position in the digital health landscape.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET. Corey McCann, M.D., Ph.D., President and CEO, will participate in the Citi analyst-hosted fireside chat to discuss Pear’s progress on market access.

Citi hosted events are intended for prospective and existing Citi clients only. To listen to the live event, please contact your Citi representative with interest.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas., including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005429/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

When is Pear Therapeutics participating in the Citi BioTech C-Suite Virtual Fireside Chat?

Pear Therapeutics will participate on January 24 at 11:00 a.m. ET.

Who is representing Pear Therapeutics at the Citi event?

Dr. Corey McCann, President and CEO, will represent Pear Therapeutics.

What is the focus of Pear Therapeutics’ discussion at the Citi event?

The discussion will focus on Pear's progress in market access for their prescription digital therapeutics.

What are prescription digital therapeutics?

Prescription digital therapeutics are software-based medicines that provide clinically validated treatment options for patients.

What are some of the FDA-approved products from Pear Therapeutics?

Pear's products include reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for chronic insomnia.